Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab

Eur J Clin Pharmacol. 2021 Jul;77(7):1065-1066. doi: 10.1007/s00228-020-03054-0. Epub 2021 Jan 7.

Authors

Benjamin Wu¹, Stephanie N Liu², Marcus Ballinger², Nitzan Sternheim², Hina Patel², Julien Mazieres³, Rene Bruno⁴

Affiliations

¹ Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. wu.benjamin@gene.com.
² Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
³ Toulouse University Hospital, Toulouse, France.
⁴ Roche, Boulogne-Billancourt, France.

PMID: 33415499
DOI: 10.1007/s00228-020-03054-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Computer Simulation
Humans

Substances

Antibodies, Monoclonal, Humanized
atezolizumab